Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | TDO2 | P48775 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17102316 | 1.00 | FFAR1 (0.43) | FFAR1LRRK2NAMPTMKNK1MKNK2 | |
| SCHEMBL1954029 | 1.00 | FFAR1 (0.43) | FFAR1LRRK2NAMPTMKNK1MKNK2 | |
| SCHEMBL28412943 | 0.92 | FFAR1 (0.41) | FFAR1LRRK2ALKMPOJAK2 | |
| SCHEMBL2358864 | 0.92 | FFAR1 (0.45) | FFAR1LRRK2MKNK1ALKMPO | |
| SCHEMBL2567994 | 0.89 | FFAR1 (0.47) | FFAR1LRRK2MKNK1MKNK2MPO | |
| SCHEMBL21588746 | 0.86 | FFAR1 (0.40) | FFAR1LRRK2ALKMPOIRAK4 | |
| SCHEMBL1987497 | 0.86 | FFAR1 (0.49) | FFAR1LRRK2MPOJAK2IRAK4 | |
| SCHEMBL21588687 | 0.85 | FFAR1 (0.40) | FFAR1LRRK2IRAK4 | |
| SCHEMBL16437406 | 0.83 | FFAR1 (0.40) | FFAR1LRRK2MPOIRAK4 | |
| SCHEMBL2572488 | 0.83 | FFAR1 (0.47) | FFAR1LRRK2MPOJAK2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138986-A1 | PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORP (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| EP-4424312-A2 | PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | Blueprint Medicines Corporation (US) | 2024-09-04 | — | — | EP | disclosed |
| US-12023319-B2 | Carboxylic acid aromatic amides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-07-02 | — | — | US | disclosed |
| EP-3953357-B1 | PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORP (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240010652-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORPORATION | 2024-01-11 | — | — | US | disclosed |
| US-20230271931-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230271931-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| EP-4229060-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES | Blueprint Medicines Corporation (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230043209-A1 | CARBOXYLIC ACID AROMATIC AMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| WO-2020210293-A1 | PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORPORATION (US) | 2020-10-15 | — | — | WO | disclosed |
| CN-110713489-A | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-3558960-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3119772-B1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| WO-2018114786-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9914735-B2 | Heteroaryl Syk inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| WO-2016169421-A1 | IMIDAZO ISOINDOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2016-10-27 | — | — | WO | disclosed |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | EVOTEC (UK) LTD. (GB) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023319-B2 | Carboxylic acid aromatic amides | DDC, PAH, NAT1 | FFAR1 507/4885LRRK2 2490/4885NAMPT 665/4885 |
| US-20230043209-A1 | CARBOXYLIC ACID AROMATIC AMIDES | DDC, PAH, NAT1 | FFAR1 507/4885LRRK2 2490/4885NAMPT 665/4885 |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | SYK, BTK, IRAK1 | FFAR1 1153/4885LRRK2 117/4885NAMPT 3336/4885 |
| US-20240010652-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | KIT, PDGFRA, PDGFRB | FFAR1 720/4885LRRK2 1570/4885NAMPT 3544/4885 |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | SYK, BTK, CD40 | FFAR1 1076/4885LRRK2 135/4885NAMPT 2728/4885 |
| US-20260138986-A1 | PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | KIT, PDGFRA, PDGFRB | FFAR1 766/4885LRRK2 278/4885NAMPT 4610/4885 |
| US-20230271931-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BDKRB1, BDKRB2, HCAR1 | FFAR1 68/4885LRRK2 2019/4885NAMPT 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.